Regarding safety, compared with muscle biopsy, FGF‐21 and GDF‐15 were noninvasive and avoided complications (bleeding and infection). Regarding cost‐effectiveness, genetic tests are the gold standard for MD diagnosis, but they are expensive. This evidence concerns the gene FGF21 and Menkes disease.